Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
2. Cgp 33101
3. Cgp-33101
4. Inovelon
1. 106308-44-5
2. Banzel
3. Inovelon
4. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
5. Cgp 33101
6. Cgp-33101
7. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4-carboxamide
8. Ruf 331
9. Xilep
10. Ruf-331
11. 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
12. E-2080
13. E2080
14. E 2080
15. Wfw942pr79
16. 1h-1,2,3-triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-
17. Ncgc00165883-02
18. 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)-
19. Dsstox_cid_26506
20. Dsstox_rid_81675
21. Dsstox_gsid_46506
22. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4 Carboxamide
23. Smr000857122
24. C10h8f2n4o
25. Cas-106308-44-5
26. Unii-wfw942pr79
27. Rufinamide [usan:inn:ban]
28. Syn111
29. Syn-111
30. Cgp33101
31. Banzel (tn)
32. Mfcd00865314
33. Rufinamide (banzel)
34. Cgp 33,101
35. Rufinamide [mi]
36. Rufinamide [inn]
37. Rufinamide [jan]
38. Rufinamide [usan]
39. Rufinamide [vandf]
40. Rufinamide [mart.]
41. Rufinamide [usp-rs]
42. Rufinamide [who-dd]
43. Rufinamide (jan/usp/inn)
44. Mls001332513
45. Mls001332514
46. Rufinamide [ema Epar]
47. Schembl230448
48. Gtpl7470
49. Zinc7782
50. Chembl1201754
51. Dtxsid1046506
52. Rufinamide [orange Book]
53. Chebi:134966
54. Hms2232m19
55. Hms3262o14
56. Hms3371a06
57. Hms3651o05
58. Hms3884g07
59. Rufinamide [usp Monograph]
60. Bcp21828
61. Hy-a0042
62. Tox21 112267
63. Tox21_112267
64. Tox21_500796
65. Bdbm50515492
66. S1256
67. Akos005145897
68. Rufinamide, >=98% (hplc), Powder
69. Tox21_112267_1
70. Ac-1429
71. Ccg-222100
72. Cs-1455
73. Db06201
74. Lp00796
75. Sb18904
76. Sdccgsbi-0633757.p001
77. Ncgc00165883-01
78. Ncgc00165883-03
79. Ncgc00165883-04
80. Ncgc00165883-11
81. Ncgc00261481-01
82. As-13861
83. Ft-0656828
84. Ft-0674479
85. R0143
86. Sw219770-1
87. C71253
88. D05775
89. Ab00918347-05
90. Ab00918347_06
91. 308r445
92. A801414
93. Q408565
94. Sr-01000842156
95. J-001568
96. Sr-01000842156-4
97. 1-[(2,6-difluorophenyl)methyl]-4-triazolecarboxamide
98. F0001-2404
99. Z1541638521
100. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazol-4-carboxamide
101. Rufinamide, United States Pharmacopeia (usp) Reference Standard
102. 1-[[2,6-bis(fluoranyl)phenyl]methyl]-1,2,3-triazole-4-carboxamide
Molecular Weight | 238.19 g/mol |
---|---|
Molecular Formula | C10H8F2N4O |
XLogP3 | 0.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 238.06661722 g/mol |
Monoisotopic Mass | 238.06661722 g/mol |
Topological Polar Surface Area | 73.8 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 282 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Banzel |
PubMed Health | Rufinamide (By mouth) |
Drug Classes | Anticonvulsant |
Drug Label | BANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H... |
Active Ingredient | Rufinamide |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 200mg; 40mg/ml; 400mg |
Market Status | Prescription |
Company | Eisai |
2 of 2 | |
---|---|
Drug Name | Banzel |
PubMed Health | Rufinamide (By mouth) |
Drug Classes | Anticonvulsant |
Drug Label | BANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H... |
Active Ingredient | Rufinamide |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 200mg; 40mg/ml; 400mg |
Market Status | Prescription |
Company | Eisai |
Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
FDA Label
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate.
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AF03
N03AF03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AF - Carboxamide derivatives
N03AF03 - Rufinamide
Absorption
The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 L/mL; Cmax, 30mg/kg/day= 8.68 L/mL; AUC (0h-12h), 10mg/kg/day= 37.847 gh/mL; AUC (0h-12h), 30mg/kg/day= 89.359 gh/mL.
Route of Elimination
Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated.
Volume of Distribution
Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear.
Rufinamide is extensively metabolized but has no active metabolites. Metabolism by carboxyesterases into inactive metabolite CGP 47292, a carboxylic acid derivative, via hydrolysis is the primary biotransformation pathway. A few minor additional metabolites were detected in urine, which appeared to be acyl-glucuronides of CGP 47292. The cytochrome P450 enzyme system or glutathiones are not involved with the metabolism of rufinamide. Rufinamide is a weak inhibitor of CYP 2E1. Rufinamide is a weak inducer of CYP 3A4 enzymes.
Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.
Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Rufinamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rufinamide, including repackagers and relabelers. The FDA regulates Rufinamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rufinamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rufinamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rufinamide supplier is an individual or a company that provides Rufinamide active pharmaceutical ingredient (API) or Rufinamide finished formulations upon request. The Rufinamide suppliers may include Rufinamide API manufacturers, exporters, distributors and traders.
click here to find a list of Rufinamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rufinamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Rufinamide active pharmaceutical ingredient (API) in detail. Different forms of Rufinamide DMFs exist exist since differing nations have different regulations, such as Rufinamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rufinamide DMF submitted to regulatory agencies in the US is known as a USDMF. Rufinamide USDMF includes data on Rufinamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rufinamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rufinamide suppliers with USDMF on PharmaCompass.
A Rufinamide written confirmation (Rufinamide WC) is an official document issued by a regulatory agency to a Rufinamide manufacturer, verifying that the manufacturing facility of a Rufinamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rufinamide APIs or Rufinamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Rufinamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Rufinamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rufinamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rufinamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rufinamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rufinamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rufinamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rufinamide suppliers with NDC on PharmaCompass.
Rufinamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rufinamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rufinamide GMP manufacturer or Rufinamide GMP API supplier for your needs.
A Rufinamide CoA (Certificate of Analysis) is a formal document that attests to Rufinamide's compliance with Rufinamide specifications and serves as a tool for batch-level quality control.
Rufinamide CoA mostly includes findings from lab analyses of a specific batch. For each Rufinamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rufinamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Rufinamide EP), Rufinamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rufinamide USP).
LOOKING FOR A SUPPLIER?